Investigations in larger numbers of anti-CD38 antibody-treated patients may provide further evidence on the changes occurring among immune effectors within the tumor microenvironment of responders and non-responders, as well as insights on their relevance for selection of subsequent treatment. This evidence concerns the gene CD38 and neoplasm.